In December 2015, I titled my ONS Connect column, “I Am Nurse, Hear Me Roar,” and addressed the outcry after a talk show host diminished Ms. Colorado, a nurse who was competing in the Ms. America competition that year. Nursing united its voice to educate the talk show host, the media, and the public.
Patients now have protection against unexpected—and often extraordinarily high—medical bills. On January 1, 2022, the Biden-Harris administration’s bipartisan No Surprises Act went into effect to ban surprise billing in private insurance for most emergency care and many instances of nonemergency care, according to the U.S. Department of Health and Human Services (HHS).
Regularly conducting geriatric assessments in older patients and using the information to guide their care reduces their risk of side effects by nearly 30%, researchers reported in study findings published in Lancet.
Immune checkpoint inhibitors (ICIs) enhance immune response against foreign antigens, such as cancer, by manipulating checkpoints that have stopped the body from fighting them. In doing so, they also increase risk of the immune system attacking healthy cells and producing inflammatory side effects, resulting in immune-related adverse events (irAEs).
Clinicians often use combination cancer therapies to overcome treatment resistance, and one of the newest options for certain patients with multiple myeloma is isatuximab, a monoclonal antibody (mAb). Approved for use in combination with pomalidomide plus dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received at least two prior therapies, isatuximab prolonged progression-free survival by nearly six months and produced an overall response rate of more than 60% in the drug’s clinical trials.
The explosion of immunotherapy in your practice? You can thank the Cancer Moonshot. New discoveries in oncodrivers for childhood cancers? Thank the Moonshot again. You can also thank it for better cancer prevention and screening strategies, attention to patient-centered care, and interprofessional collaboration among oncology scientists and clinicians.
For better or for worse, the COVID-19 pandemic has affected nearly every aspect of life as we know it. As the virus evolves, so do we—from individuals to health systems, the country, public health policies, and more.
African American nurse leaders in ONS have paved the way in eliminating cancer disparities, identifying and tackling social determinants of health, and providing Black communities with educational and clinical resources.
Biomarker testing is an essential tool when choosing the right treatment for many advanced solid cancers. However, tissue-based testing may take weeks to get results with a chance that not enough tissue was collected to complete the entire biomarker panel. Blood draw–based liquid biopsies may be a useful alternative to identify a tumor’s biomarker details and can be performed by testing for circulating tumor DNA (ctDNA).
Combining a CDK4/6 inhibitor and fulvestrant improves overall survival consistently among patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to a U.S. Food and Drug Administration (FDA) analysis. The agency reported the findings in Lancet Oncology.